// App-Quantinova.ai

: Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.

Researchers

Presenter

  • Abdenour Nabid

Principal Investigators

  • Marie-Pierre Garant

  • Eric Vigneault

  • Luis Souhami

  • Celine Lemaire

  • Marc-Andre Brassard

  • Boris Bahoric

  • Robert Archambault

  • Francois Vincent

  • Thu-Van Nguyen-Huynh

  • Redouane Bettahar

  • Derek R Wilke

Medical Centers

  • Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

  • Centre Hospitalier Universitaire de Quebec, Quebec City, QC, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

  • Centre de Sante et Services Sociaux de Chicoutimi, Chicoutimi, QC, Canada

  • Hopital General Juif de Montreal, Montreal, QC, Canada

  • Hopital de Gatineau, Gatineau, QC, Canada

  • Centre Hospitalier Regional de Trois-Rivieres, Trois-Rivieres, QC, Canada

  • Hopital Notre-Dame, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada

  • Centre Hospitalier Regional de Rimouski - Centre de Cancer, Rimouski, QC, Canada

  • Nova Scotia Cancer Center, Halifax, NS, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bicalutamide

  • Goserelin

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT00223145

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved